Structure via PubChem · Public domain (PubChem)
ensitrelvir
Sign in to saveAlso known as 1-(2,4,5-trifluorobenzyl)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-(6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-1,3,5-triazinane-2,4-dione, S-217622
thumb|right|75px|Xocova in a Japanese blister pack
Key facts
- Drug.image
- Ensitrelvir.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Xocova
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- J05
- Drug.ATC_suffix
- AE11
- Drug.legal_status
- JP: Rx-only
- Drug.elimination_half life
- 42–48 hours
- Drug.CAS_number
- 2647530-73-0
- Drug.CAS_number2
- 2757470-18-9
- Drug.PubChem
- 162533924
- Drug.DrugBank
- DB18834
- Drug.ChemSpiderID
- 115007411
- Drug.UNII
- PX665RAA3H
- Drug.KEGG
- D12353
- Drug.synonyms
- S-217622
- Drug.IUPAC_name
- 1-(2,4,5-Trifluorobenzyl)-3-[(1-methyl-1H-1,2,4-triazol-3-yl)methyl]-(6E)-6-[(6-chloro-2-methyl-2H-indazol-5-yl)imino]-1,3,5-triazinane-2,4-dione
- Drug.C
- 22
via Wikipedia infobox
Chemical data
- Formula
- C22H17ClF3N9O2
- Molecular weight
- 531.9 g/mol
- IUPAC name
- 6-[(6-chloro-2-methylindazol-5-yl)amino]-3-[(1-methyl-1,2,4-triazol-3-yl)methyl]-1-[(2,4,5-trifluorophenyl)methyl]-1,3,5-triazine-2,4-dione
- SMILES
- CN1C=C2C=C(C(=CC2=N1)Cl)NC3=NC(=O)N(C(=O)N3CC4=CC(=C(C=C4F)F)F)CC5=NN(C=N5)C
- InChIKey
- QMPBBNUOBOFBFS-UHFFFAOYSA-N
- XLogP
- 2.5
- Polar surface area
- 114 Ų
- H-bond donors
- 1
- H-bond acceptors
- 8
- Formal charge
- 0
via PubChem
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 531.1145831240002
Show 4 more facts
- subject has role
- antiviral drug
- canonical SMILES
- Cn1cnc(CN2C(=O)N(Cc3cc(F)c(F)cc3F)C(=N\c3cc4cn(C)nc4cc3Cl)\NC2=O)n1
- Commons category
- Ensitrelvir
- chemical formula
- C₂₂H₁₇ClF₃N₉O₂
Sources (1)
via Wikidata · CC0
~5 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- History
- Society and culture
- Legal status
- Names
- Research
- References
thumb|right|75px|Xocova in a Japanese blister pack
Ensitrelvir, sold under the brand name Xocova is an antiviral medication used as a treatment for COVID-19. It was developed by Shionogi in partnership with Hokkaido University and acts as an orally active 3C-like protease inhibitor. It is taken by mouth.
Excerpted from Wikipedia’s “ensitrelvir” article, available under the CC BY-SA 4.0 licence.